Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Analysis of factors associated with clinical response in glofitamab's treatment of relapsed or refractory (R/R) large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HJHongmei JingPeking University

Discussion

Loading...

Member takes

Implication

Retrospective analysis reveals cytokine expression and gene expression impact treatment response in R/R large B-cell lymphoma.

Key Points

  • This research evaluates factors associated with treatment response to glofitamab in relapsed large B-cell lymphoma patients.
  • Retrospective evaluation of 15 patients treated with glofitamab after at least two prior therapies.
  • Analysis included baseline characteristics, treatment details, immune subset levels, gene expression, and cytokine measurements.
  • Multivariate analysis conducted to identify independent predictors of treatment response.
  • 46% of patients achieved complete response (CR) with glofitamab treatment.
  • No significant correlation found between baseline immune subsets and CR.
  • Higher levels of CD4/CD8 memory T cells were observed in CR patients, but cytokine levels showed no significant differences.

Cite This Study

Hongmei Jing (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d202https://doi.org/10.1182/blood-2025-7262
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Biomarker analysis to unravel mechanisms of resistance to glofitamab monotherapy in large B cell lymphoma2025
  2. 2Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study2025
  3. 3Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  4. 4Efficacy, safety, and T-cell population dynamics of glofitamab monotherapy in relapsed/refractory B-cell lymphoma2025
  5. 5A chemo-free tumor microenvironment (TME) reshaping regimen combining glofitamab induces a high CR rate in relapsed/refractory diffuse large B cell lymphoma (DLBCL)2025